A Multicenter, Two Part, Phase 1B Study Evaluating Alternative Routes of Administration of CMP-001 in Combination With Pembrolizumab in Subjects With Advanced Melanoma

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 09 Aug 2022

Price :

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

Drugs Pembrolizumab (Primary) ; Vidutolimod (Primary) ; Vidutolimod (Primary)
Indications Malignant melanoma
Focus Adverse reactions
Sponsors Regeneron Pharmaceuticals

08 Apr 2022 Results published in the Checkmate Pharmaceuticals Media Release.
08 Apr 2022 According to a Checkmate Pharmaceuticals media release, biomarker signature data from the study will be presented at the 2022 American Association for Cancer Research (AACR) Annual Meeting.
06 Dec 2021 Status changed from active, no longer recruiting to completed.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com